Brexucabtagene autoleucel (brexu-cel; formerly known as KTE-X19) was the first approved CD19-targeted CAR T-cell therapy for R/R MCL based on findings from the phase 2 ZUMA-2 trial, which demonstrated an ORR of 93% and CR rate of 67% [12••]. The gene discussed is CD19; the disease is mantle cell lymphoma.